Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma
| Autor: | Sumati Gupta, Theodore Stewart Gourdin, Aaron Hardin, Petros Grivas, Lesli A. Kiedrowski, Roby Antony Thomas, Nicholas J. Vogelzang, Guru Sonpavde, Kimberly M. Hamann, Bishoy Faltas |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Bladder Cancer. 7:143-148 |
| ISSN: | 2352-3735 2352-3727 |
| Popis: | Detecting genomic alterations (GAs) in advanced urothelial carcinoma (aUC) can expand treatment options by identifying candidates for targeted therapies. Erdafitinib is FDA-approved for patients with platinum-refractory aUC with activating mutation or fusion in FGFR2/3. We explored the prevalence and spectrum of FGFR2/3 GAs identified with plasma cfDNA NGS testing (Guardant360) in 997 patients with aUC. FGFR2/3 GAs were detected in 201 patients (20%) with characterized activating GAs in 141 (14%). Our results indicate the Guardant360-based FGFR2/3 GA detection rate is similar to those described from previous studies employing tumor tissue testing, suggesting that plasma-based cfDNA NGS may non-invasively identify candidates for anti-FGFR targeted therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|